Literature DB >> 8702581

The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation.

F S Monteclaro1, I F Charo.   

Abstract

The chemoattractant cytokines, MCP-1 (monocyte chemoattractant protein) and MIP-1alpha (macrophage inflammatory protein), are recognized by highly homologous but distinct receptors. To identify receptor domains involved in determining ligand specificity, we created a series of chimeric MCP-1 and RANTES (regulated on activation, normal T cell expressed and secreted)/MIP-1alpha receptors that progressively interchanged the amino terminus and each of the three extracellular loops. Radiolabeled MCP-1 bound with high affinity to the wild-type MCP-1 receptor, but not to the RANTES/MIP-1alpha receptor (C-C CKR-1). Chimeras that retained the amino-terminal extension of the MCP-1 receptor bound MCP-1 with high affinity. In contrast, chimeric MCP-1 receptors, in which the wild-type amino terminus was replaced with the corresponding portion of the RANTES/MIP-1alpha receptor, bound MCP-1 with low affinity. These data indicate that the amino terminus of the MCP-1 receptor is necessary for high affinity binding of the ligand. Very different results were obtained using the RANTES/MIP-1alpha receptor. Radiolabeled MIP-1alpha bound with high affinity to chimeras that expressed the extracellular loops of the RANTES/MIP-1alpha receptor. In contrast to the MCP-1 receptor, substitution of the wild-type amino-terminal extension had little or no effect on MIP-1alpha binding. For the MCP-1, but not the RANTES/MIP-1alpha receptor, the presence of the wild-type amino terminus also significantly lowered the ligand concentration required for maximal signaling. We conclude that the amino-terminal extension of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, is critically involved in ligand binding and signal transduction. These data reveal significant functional differences between the two C-C chemokine receptors and suggest a two-step mechanism for activation of the MCP-1 receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702581     DOI: 10.1074/jbc.271.32.19084

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 3.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

Review 4.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

5.  Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1.

Authors:  Julie Sanchez; Zil E Huma; J Robert Lane; Xuyu Liu; Jessica L Bridgford; Richard J Payne; Meritxell Canals; Martin J Stone
Journal:  J Biol Chem       Date:  2018-12-19       Impact factor: 5.157

6.  Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach.

Authors:  Stefanie Thiele; Anne Steen; Pia C Jensen; Jacek Mokrosinski; Thomas M Frimurer; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

7.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Authors:  S Qin; J B Rottman; P Myers; N Kassam; M Weinblatt; M Loetscher; A E Koch; B Moser; C R Mackay
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

8.  Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis.

Authors:  Bryan S Stephens; Tony Ngo; Irina Kufareva; Tracy M Handel
Journal:  Sci Signal       Date:  2020-07-14       Impact factor: 8.192

Review 9.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

Review 10.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.